177Lu-RAD204 vs Sugemalimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
177Lu-RAD204
Developed by Radiopharm Theranostics, Ltd
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT06305962 (registry estimate)
No aligned efficacy figure on record for this race.
Sugemalimab · Cejemly
Marketed by CStone Pharmaceuticals and partners
NCT03728556 · Phase 3 · completed
In this randomized, quadruple-blind, placebo-controlled Phase 3 trial, 381 patients with stage III lung cancer who had completed chemoradiotherapy were randomized to sugemalimab or placebo. Sugemalimab significantly reduced the risk of progression or death compared with placebo (median progression-free survival 10.5 vs 6.2 months).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2027 · NCT07247227 (registry estimate)
Reported efficacy
Progress Free Survival (PFS) (from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 30 months.): Progression-free survival (BICR-assessed), GEMSTONE-301: median PFS 10.5 months (sugemalimab) vs 6.2 months (placebo); HR 0.65, 95% CI 0.50-0.84 (met)
Result source: NCT03728556
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | 177Lu-RAD204 | Sugemalimab |
|---|---|---|
| PFS, median | —Not reported | 10.5 vs 6.2a+4.3 vs placeboNCT03728556 |
| OS, median | —Not reported | —Not posted · NCT03728556 |
| ORR | —Not reported | —Not posted · NCT03728556 |
| Duration of response, median | —Not reported | —Not posted · NCT03728556 |
PFS, median
- 177Lu-RAD204
- —Not reported
- Sugemalimab
- 10.5 vs 6.2a+4.3 vs placeboNCT03728556
OS, median
- 177Lu-RAD204
- —Not reported
- Sugemalimab
- —Not posted · NCT03728556
ORR
- 177Lu-RAD204
- —Not reported
- Sugemalimab
- —Not posted · NCT03728556
Duration of response, median
- 177Lu-RAD204
- —Not reported
- Sugemalimab
- —Not posted · NCT03728556
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
177Lu-RAD204: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sugemalimab
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 177Lu-RAD204's landscape · Sugemalimab's landscape